Loading…
Reported covered position: See prior filing
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: CHILDREN'S HOSPITAL AND HEALTH SYSTEM, INC. · Firm: BGR GOVERNMENT AFFAIRS
Health care reform and regulatory implementation and funding, Medicaid, Graduate Medical Education; CHIP Reauthorization; DSH Payments; FY'25 federal appropriations; mental health reform; H.R. 1 One Big Beautiful Bill Act
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: CHILDREN'S HOSPITAL AND HEALTH SYSTEM, INC. · Firm: BGR GOVERNMENT AFFAIRS
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
MLK COMMUNITY HEALTHCARE via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide guidance and advocacy with regard to federal regulations and legislation that could impact non-profit health care providers generally, or MLK Community Healthcare specifically.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
STRYKER CORPORATION via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Source: Senate LDA
| AKEBIA THERAPEUTICS, INC. |
| 27 |
| 2020–2026 |
| EDWARDS LIFESCIENCES LLC | 27 | 2020–2026 |
| MLK COMMUNITY HEALTHCARE | 27 | 2021–2026 |
| SCP-HEALTH | 27 | 2020–2026 |
| BIOTECHNOLOGY INNOVATION ORGANIZATION | 26 | 2020–2026 |
| CENTENE CORPORATION | 26 | 2020–2026 |
| FRESENIUS MEDICAL CARE | 26 | 2020–2026 |
| LOCKTON MANAGEMENT, LLC | 26 | 2020–2026 |
| PTC THERAPEUTICS | 26 | 2020–2026 |
| AMEDISYS, INC. | 25 | 2020–2026 |
| CHILDREN'S HOSPITAL AND HEALTH SYSTEM, INC. | 25 | 2020–2026 |
| GLAXOSMITHKLINE, INC. | 25 | 2020–2026 |
| MATRIX MEDICAL NETWORK | 25 | 2020–2026 |
| STRYKER CORPORATION | 25 | 2020–2026 |
| KIDNEY CARE PARTNERS | 24 | 2020–2026 |
| OAK STREET HEALTH D/B/A CVS HEALTH | 23 | 2021–2026 |
| PFIZER, INC. | 23 | 2021–2026 |
| ABIOMED INC | 22 | 2020–2025 |
| SENIOR CARE PHARMACY COALITION | 22 | 2020–2025 |
| ALLIANCE FOR REGENERATIVE MEDICINE | 21 | 2022–2026 |
| AMGEN, INC. | 21 | 2020–2025 |
| FINDHELP | 21 | 2021–2026 |
| LUMEXA IMAGING, INC. (FKA US RADIOLOGY SPECIALISTS) | 21 | 2021–2026 |
| RADIOLOGY PARTNERS | 21 | 2021–2026 |
| REAL TIME MEDICAL SYSTEMS | 21 | 2021–2026 |
| ALG SENIOR LLC | 18 | 2020–2024 |
| THE ASSISTANCE FUND | 18 | 2021–2024 |
| BAYER CORPORATION | 17 | 2020–2024 |
| NOVARTIS | 17 | 2023–2026 |
| BIOMARIN PHARMACEUTICAL INC. | 16 | 2023–2026 |
| HORIZON PHARMA | 15 | 2020–2023 |
| ACADEMY OF NUTRITION & DIETETICS | 14 | 2024–2026 |
| U.S. ACUTE CARE SOLUTIONS, LLC | 13 | 2020–2023 |
| ADVOCATE HEALTH | 12 | 2024–2026 |
| ASSOCIATION OF DENTAL SUPPORT ORGANIZATIONS | 12 | 2021–2024 |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 12 | 2020–2023 |
| SIEMENS HEALTHINEERS | 12 | 2020–2023 |
| U.S. ANESTHESIA PARTNERS, INC. | 12 | 2020–2023 |
| BREAKTHROUGH T1D (F/K/A JDRF) | 11 | 2024–2026 |
| EPIGENOMICS INC. | 11 | 2020–2022 |
| GRADY HEALTH SYSTEM | 11 | 2024–2026 |
| NYU LANGONE HEALTH | 11 | 2024–2026 |
| BAUDAX BIO, INC. (FORMERLY KNOWN AS RECRO PHARMA, INC.) | 10 | 2020–2022 |
| PROLACTA BIOSCIENCE, INC. | 10 | 2024–2026 |
| STAMFORD HEALTH | 10 | 2025–2026 |
| UROGEN PHARMA, INC. | 10 | 2022–2024 |
| LYNDRA THERAPEUTICS | 9 | 2020–2022 |
| MIND SPRINGS HEALTH | 9 | 2022–2024 |
| NEKTAR THERAPEUTICS | 9 | 2020–2022 |
| IOWA PRIMARY CARE ASSOCIATION (NATIONAL PRIMARY CARE ASSOCIATION HUB) | 8 | 2025–2026 |
| NATIONAL ALLIANCE FOR CARE AT HOME | 8 | 2025–2026 |
| TEXAS ESSENTIAL HEALTHCARE PARTNERSHIPS | 8 | 2025–2026 |
| Zogenix, Inc. | 8 | 2020–2022 |
| APPLIED BIOLOGICS | 7 | 2024–2025 |
| QUOTE VELOCITY | 6 | 2024–2025 |
| ADVANCED DIAGNOSTICS HEALTHCARE SYSTEM | 4 | 2024 |
| CDR MAGUIRE | 4 | 2022 |
| DISPOSERX, INC. | 4 | 2020–2021 |
| EIGER BIOPHARMACEUTICALS, INC. | 4 | 2020–2021 |
| FEDERATION OF AMERICAN HOSPITALS | 4 | 2026 |
| HELLO HEART, INC | 4 | 2026 |
| LARKIN HEALTH SYSTEM | 4 | 2024 |
| REGENERON PHARMACEUTICALS, INC. | 4 | 2025–2026 |
| ShiftKey, LLC | 4 | 2023–2024 |
| AMBULNZ | 3 | 2020 |
| BECTON, DICKINSON AND COMPANY | 3 | 2026 |
| BIOMERIEUX, INC. | 3 | 2024–2025 |
| CARLSMED, INC. | 3 | 2024 |
| KING'S DAUGHTERS MEDICAL CENTER | 3 | 2026 |
| PHI HEALTH, LLC, D/B/A PHI AIR MEDICAL | 3 | 2026 |
| PREMIA SPINE | 3 | 2026 |
| AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION | 2 | 2026 |
| CARDINAL HEALTH | 2 | 2026 |
| NASSAU HEALTH SYSTEM CORP. | 2 | 2025 |
| NEPHROLOGY ASSOCIATES OF NORTHERN ILLINOIS AND INDIANA | 2 | 2021 |
| AMERICAN ASSOCIATION OF NURSE ANESTHESIOLOGY | 1 | 2025 |
| PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION | 1 | 2023 |
| SAS INSTITUTE, INC. | 1 | 2020 |
Health care reform and regulatory implementation and funding, Medicaid, Graduate Medical Education; CHIP Reauthorization; DSH Payments; FY'25 federal appropriations; mental health reform; H.R. 1 One Big Beautiful Bill Act
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: CHILDREN'S HOSPITAL AND HEALTH SYSTEM, INC. · Firm: BGR GOVERNMENT AFFAIRS
Health care reform and regulatory implementation and funding, Medicaid, Graduate Medical Education; CHIP Reauthorization; DSH Payments; FY'25 federal appropriations; mental health reform; H.R. 1 One Big Beautiful Bill Act
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies and EPIC Act
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies, EPIC Act; Most Favored Nation (MFN) policy, drug pricing policies
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies, EPIC Act; Most Favored Nation (MFN) policy, drug pricing policies
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies and EPIC Act
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies and EPIC Act
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies, EPIC Act; Most Favored Nation (MFN) policy, drug pricing policies
Preserving Access to Home Health Act of 2022
Client: AMEDISYS, INC. · Firm: BGR GOVERNMENT AFFAIRS
Strategic guidance and counsel on home health reimbursement and policy including The Preserving Access to Home Health Act (S. 4605/ H.R. 8581)
Preserving Access to Home Health Act of 2022
Client: AMEDISYS, INC. · Firm: BGR GOVERNMENT AFFAIRS
Strategic guidance and counsel on home health reimbursement and policy including The Preserving Access to Home Health Act (S. 4605/ H.R. 8581)
Restore Protections for Dialysis Patients Act
Client: KIDNEY CARE PARTNERS · Firm: BGR GOVERNMENT AFFAIRS
Provide guidance, and strategic counsel on federal regulatory policy and legislative issues affecting the quality of kidney care and treatment including the ESRD Prospective Payment System Regulation and the Chronic Kidney Disease Improvement in Research and Treatment Act, Restore Protections for Dialysis Patients Act (H.R. 8594/S. 4750) and other bills impacting kidney care.
Preserving Access to Home Health Act of 2022
Client: AMEDISYS, INC. · Firm: BGR GOVERNMENT AFFAIRS
Strategic guidance and counsel on home health reimbursement and policy including The Preserving Access to Home Health Act (S. 4605/ H.R. 8581)
Preserving Access to Home Health Act of 2022
Client: AMEDISYS, INC. · Firm: BGR GOVERNMENT AFFAIRS
Strategic guidance and counsel on home health reimbursement and policy including The Preserving Access to Home Health Act (S. 4605/ H.R. 8581)
Restore Protections for Dialysis Patients Act
Client: KIDNEY CARE PARTNERS · Firm: BGR GOVERNMENT AFFAIRS
Provide guidance, and strategic counsel on federal regulatory policy and legislative issues affecting the quality of kidney care and treatment including the ESRD Prospective Payment System Regulation and the Chronic Kidney Disease Improvement in Research and Treatment Act, Restore Protections for Dialysis Patients Act (H.R. 8594/S. 4750) and other bills impacting kidney care.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: CHILDREN'S HOSPITAL AND HEALTH SYSTEM, INC. · Firm: BGR GOVERNMENT AFFAIRS
Health care reform and regulatory implementation and funding, Medicaid, Graduate Medical Education; CHIP Reauthorization; DSH Payments; FY'25 federal appropriations; mental health reform; H.R. 1 One Big Beautiful Bill Act
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: CHILDREN'S HOSPITAL AND HEALTH SYSTEM, INC. · Firm: BGR GOVERNMENT AFFAIRS
Health care reform and regulatory implementation and funding, Medicaid, Graduate Medical Education; CHIP Reauthorization; DSH Payments; FY'25 federal appropriations; mental health reform; H.R. 1 One Big Beautiful Bill Act
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: CHILDREN'S HOSPITAL AND HEALTH SYSTEM, INC. · Firm: BGR GOVERNMENT AFFAIRS
Health care reform and regulatory implementation and funding, Medicaid, Graduate Medical Education; CHIP Reauthorization; DSH Payments; FY'25 federal appropriations; mental health reform; H.R. 1 One Big Beautiful Bill Act
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies, EPIC Act; Most Favored Nation (MFN) policy, drug pricing policies
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies and EPIC Act
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, and biopharma innovation policies.
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, and biopharma innovation policies.
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies and EPIC Act
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies, EPIC Act; Most Favored Nation (MFN) policy, drug pricing policies
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies and EPIC Act
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies and EPIC Act
Preserving Patient Access to Long-Term Care Pharmacies Act
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting the long-term care pharmacy industry and guidance on H.R. 5031 Preserving Patient Access to Long-Term Care Pharmacies Act
Preserving Access to Home Health Act of 2022
Client: AMEDISYS, INC. · Firm: BGR GOVERNMENT AFFAIRS
Strategic guidance and counsel on home health reimbursement and policy including The Preserving Access to Home Health Act of 2022 (S. 4605/ H.R. 8581)
Preserving Access to Home Health Act of 2022
Client: AMEDISYS, INC. · Firm: BGR GOVERNMENT AFFAIRS
Strategic guidance and counsel on home health reimbursement and policy including The Preserving Access to Home Health Act (S. 4605/ H.R. 8581)
Preserving Access to Home Health Act of 2022
Client: AMEDISYS, INC. · Firm: BGR GOVERNMENT AFFAIRS
Strategic guidance and counsel on home health reimbursement and policy including The Preserving Access to Home Health Act (S. 4605/ H.R. 8581)
Preserving Access to Home Health Act of 2022
Client: AMEDISYS, INC. · Firm: BGR GOVERNMENT AFFAIRS
Strategic guidance and counsel on home health reimbursement and policy including The Preserving Access to Home Health Act (S. 4605/ H.R. 8581)
Restore Protections for Dialysis Patients Act
Client: KIDNEY CARE PARTNERS · Firm: BGR GOVERNMENT AFFAIRS
Provide guidance, and strategic counsel on federal regulatory policy and legislative issues affecting the quality of kidney care and treatment including the ESRD Prospective Payment System Regulation and the Chronic Kidney Disease Improvement in Research and Treatment Act, Restore Protections for Dialysis Patients Act (H.R. 8594/S. 4750) and other bills impacting kidney care.
Restore Protections for Dialysis Patients Act
Client: KIDNEY CARE PARTNERS · Firm: BGR GOVERNMENT AFFAIRS
Provide guidance, and strategic counsel on federal regulatory policy and legislative issues affecting the quality of kidney care and treatment including the ESRD Prospective Payment System Regulation and the Chronic Kidney Disease Improvement in Research and Treatment Act, Restore Protections for Dialysis Patients Act (H.R. 8594/S. 4750) and other bills impacting kidney care.
Restore Protections for Dialysis Patients Act
Client: KIDNEY CARE PARTNERS · Firm: BGR GOVERNMENT AFFAIRS
Provide guidance, and strategic counsel on federal regulatory policy and legislative issues affecting the quality of kidney care and treatment including the ESRD Prospective Payment System Regulation and the Chronic Kidney Disease Improvement in Research and Treatment Act, Restore Protections for Dialysis Patients Act (H.R. 8594/S. 4750) and other bills impacting kidney care.
Restore Protections for Dialysis Patients Act
Client: KIDNEY CARE PARTNERS · Firm: BGR GOVERNMENT AFFAIRS
Provide guidance, and strategic counsel on federal regulatory policy and legislative issues affecting the quality of kidney care and treatment including the ESRD Prospective Payment System Regulation and the Chronic Kidney Disease Improvement in Research and Treatment Act, Restore Protections for Dialysis Patients Act (H.R. 8594/S. 4750) and other bills impacting kidney care.
Preserving Access to Home Health Act of 2022
Client: AMEDISYS, INC. · Firm: BGR GOVERNMENT AFFAIRS
Strategic guidance and counsel on home health reimbursement and policy including The Preserving Access to Home Health Act (S. 4605/ H.R. 8581)
Preserving Access to Home Health Act of 2022
Client: AMEDISYS, INC. · Firm: BGR GOVERNMENT AFFAIRS
Strategic guidance and counsel on home health reimbursement and policy including The Preserving Access to Home Health Act (S. 4605/ H.R. 8581)
Preserving Access to Home Health Act of 2022
Client: AMEDISYS, INC. · Firm: BGR GOVERNMENT AFFAIRS
Strategic guidance and counsel on home health reimbursement and policy including The Preserving Access to Home Health Act (S. 4605/ H.R. 8581)
Preserving Access to Home Health Act of 2022
Client: AMEDISYS, INC. · Firm: BGR GOVERNMENT AFFAIRS
Strategic guidance and counsel on home health reimbursement and policy including The Preserving Access to Home Health Act of 2022 (S. 4605/ H.R. 8581)
Restore Protections for Dialysis Patients Act
Client: KIDNEY CARE PARTNERS · Firm: BGR GOVERNMENT AFFAIRS
Provide guidance, and strategic counsel on federal regulatory policy and legislative issues affecting the quality of kidney care and treatment including the ESRD Prospective Payment System Regulation and the Chronic Kidney Disease Improvement in Research and Treatment Act, Restore Protections for Dialysis Patients Act (H.R. 8594/S. 4750) and other bills impacting kidney care.
Restore Protections for Dialysis Patients Act
Client: KIDNEY CARE PARTNERS · Firm: BGR GOVERNMENT AFFAIRS
Provide guidance, and strategic counsel on federal regulatory policy and legislative issues affecting the quality of kidney care and treatment including the ESRD Prospective Payment System Regulation and the Chronic Kidney Disease Improvement in Research and Treatment Act, Restore Protections for Dialysis Patients Act (H.R. 8594/S. 4750) and other bills impacting kidney care.
Restore Protections for Dialysis Patients Act
Client: KIDNEY CARE PARTNERS · Firm: BGR GOVERNMENT AFFAIRS
Provide guidance, and strategic counsel on federal regulatory policy and legislative issues affecting the quality of kidney care and treatment including the ESRD Prospective Payment System Regulation and the Chronic Kidney Disease Improvement in Research and Treatment Act, Restore Protections for Dialysis Patients Act (H.R. 8594/S. 4750) and other bills impacting kidney care.
Restore Protections for Dialysis Patients Act
Client: KIDNEY CARE PARTNERS · Firm: BGR GOVERNMENT AFFAIRS
Provide guidance, and strategic counsel on federal regulatory policy and legislative issues affecting the quality of kidney care and treatment including the ESRD Prospective Payment System Regulation and the Chronic Kidney Disease Improvement in Research and Treatment Act, Restore Protections for Dialysis Patients Act (H.R. 8594/S. 4750) and other bills impacting kidney care.
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patient out of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act S. 476/H.R.5547, biopharma innovation policies and Rare Pediatric Disease Priority Review Voucher program policies.
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patient out of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act S. 476/H.R.5547, and biopharma innovation policies.
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patient out of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act S. 476/H.R.5547, and biopharma innovation policies.
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patient out of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act S. 476/H.R.5547, and biopharma innovation policies.
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patient out of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act S. 476/H.R.5547, and biopharma innovation policies.
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patient out of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act S. 476/H.R.5547, and biopharma innovation policies.
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patient out of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act S. 476/H.R.5547, and biopharma innovation policies.
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patient out of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act S. 476/H.R.5547, and biopharma innovation policies.
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patient out of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act S. 476/H.R.5547, and biopharma innovation policies.
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patient out of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act S. 476/H.R.5547, and biopharma innovation policies.
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patient out of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act S. 476/H.R.5547, biopharma innovation policies and Rare Pediatric Disease Priority Review Voucher program policies.
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patient out of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act S. 476/H.R.5547, and biopharma innovation policies.
Preserving Access to Home Health Act of 2022
Client: AMEDISYS, INC. · Firm: BGR GOVERNMENT AFFAIRS
Strategic guidance and counsel on home health reimbursement and policy including The Preserving Access to Home Health Act of 2022 (S. 4605/ H.R. 8581)
Preserving Access to Home Health Act of 2022
Client: AMEDISYS, INC. · Firm: BGR GOVERNMENT AFFAIRS
Strategic guidance and counsel on home health reimbursement and policy including The Preserving Access to Home Health Act of 2022 (S. 4605/ H.R. 8581)
Preserving Access to Home Health Act of 2022
Client: AMEDISYS, INC. · Firm: BGR GOVERNMENT AFFAIRS
Strategic guidance and counsel on home health reimbursement and policy including The Preserving Access to Home Health Act of 2022 (S. 4605/ H.R. 8581)
Preserving Access to Home Health Act of 2022
Client: AMEDISYS, INC. · Firm: BGR GOVERNMENT AFFAIRS
Strategic guidance and counsel on home health reimbursement and policy including The Preserving Access to Home Health Act of 2022 (S. 4605/ H.R. 8581)
Restore Protections for Dialysis Patients Act
Client: KIDNEY CARE PARTNERS · Firm: BGR GOVERNMENT AFFAIRS
Provide guidance, and strategic counsel on federal regulatory policy and legislative issues affecting the quality of kidney care and treatment including the ESRD Prospective Payment System Regulation and the Chronic Kidney Disease Improvement in Research and Treatment Act, Restore Protections for Dialysis Patients Act (H.R. 8594/S. 4750) and other bills impacting kidney care.
Restore Protections for Dialysis Patients Act
Client: KIDNEY CARE PARTNERS · Firm: BGR GOVERNMENT AFFAIRS
Provide guidance, and strategic counsel on federal regulatory policy and legislative issues affecting the quality of kidney care and treatment including the ESRD Prospective Payment System Regulation and the Chronic Kidney Disease Improvement in Research and Treatment Act, Restore Protections for Dialysis Patients Act (H.R. 8594/S. 4750) and other bills impacting kidney care.
Restore Protections for Dialysis Patients Act
Client: KIDNEY CARE PARTNERS · Firm: BGR GOVERNMENT AFFAIRS
Provide guidance, and strategic counsel on federal regulatory policy and legislative issues affecting the quality of kidney care and treatment including the ESRD Prospective Payment System Regulation and the Chronic Kidney Disease Improvement in Research and Treatment Act, Restore Protections for Dialysis Patients Act (H.R. 8594/S. 4750) and other bills impacting kidney care.
Restore Protections for Dialysis Patients Act
Client: KIDNEY CARE PARTNERS · Firm: BGR GOVERNMENT AFFAIRS
Provide guidance, and strategic counsel on federal regulatory policy and legislative issues affecting the quality of kidney care and treatment including the ESRD Prospective Payment System Regulation and the Chronic Kidney Disease Improvement in Research and Treatment Act, Restore Protections for Dialysis Patients Act (H.R. 8594/S. 4750) and other bills impacting kidney care.
Preserving Access to Home Health Act of 2022
Client: AMEDISYS, INC. · Firm: BGR GOVERNMENT AFFAIRS
Strategic guidance and counsel on home health reimbursement and policy including The Preserving Access to Home Health Act of 2022 (S. 4605/ H.R. 8581)
Preserving Access to Home Health Act of 2022
Client: AMEDISYS, INC. · Firm: BGR GOVERNMENT AFFAIRS
Strategic guidance and counsel on home health reimbursement and policy including The Preserving Access to Home Health Act of 2022 (S. 4605/ H.R. 8581)
Preserving Access to Home Health Act of 2022
Client: AMEDISYS, INC. · Firm: BGR GOVERNMENT AFFAIRS
Strategic guidance and counsel on home health reimbursement and policy including The Preserving Access to Home Health Act of 2022 (S. 4605/ H.R. 8581)
Preserving Access to Home Health Act of 2022
Client: AMEDISYS, INC. · Firm: BGR GOVERNMENT AFFAIRS
Strategic guidance and counsel on home health reimbursement and policy including The Preserving Access to Home Health Act of 2022 (S. 4605/ H.R. 8581)
Restore Protections for Dialysis Patients Act
Client: KIDNEY CARE PARTNERS · Firm: BGR GOVERNMENT AFFAIRS
Provide guidance, and strategic counsel on federal regulatory policy and legislative issues affecting the quality of kidney care and treatment including the ESRD Prospective Payment System Regulation and the Chronic Kidney Disease Improvement in Research and Treatment Act, Restore Protections for Dialysis Patients Act (H.R. 8594/S. 4750) and other bills impacting kidney care.
Restore Protections for Dialysis Patients Act
Client: KIDNEY CARE PARTNERS · Firm: BGR GOVERNMENT AFFAIRS
Provide guidance, and strategic counsel on federal regulatory policy and legislative issues affecting the quality of kidney care and treatment including the ESRD Prospective Payment System Regulation and the Chronic Kidney Disease Improvement in Research and Treatment Act, Restore Protections for Dialysis Patients Act (H.R. 8594/S. 4750) and other bills impacting kidney care.
Restore Protections for Dialysis Patients Act
Client: KIDNEY CARE PARTNERS · Firm: BGR GOVERNMENT AFFAIRS
Provide guidance, and strategic counsel on federal regulatory policy and legislative issues affecting the quality of kidney care and treatment including the ESRD Prospective Payment System Regulation and the Chronic Kidney Disease Improvement in Research and Treatment Act, Restore Protections for Dialysis Patients Act (H.R. 8594/S. 4750) and other bills impacting kidney care.
Restore Protections for Dialysis Patients Act
Client: KIDNEY CARE PARTNERS · Firm: BGR GOVERNMENT AFFAIRS
Provide guidance, and strategic counsel on federal regulatory policy and legislative issues affecting the quality of kidney care and treatment including the ESRD Prospective Payment System Regulation and the Chronic Kidney Disease Improvement in Research and Treatment Act, Restore Protections for Dialysis Patients Act (H.R. 8594/S. 4750) and other bills impacting kidney care.
Preserving Access to Home Health Act of 2022
Client: AMEDISYS, INC. · Firm: BGR GOVERNMENT AFFAIRS
Strategic guidance and counsel on home health reimbursement and policy including The Preserving Access to Home Health Act of 2022 (S. 4605/ H.R. 8581)
Preserving Access to Home Health Act of 2022
Client: AMEDISYS, INC. · Firm: BGR GOVERNMENT AFFAIRS
Strategic guidance and counsel on home health reimbursement and policy including The Preserving Access to Home Health Act of 2022 (S. 4605/ H.R. 8581)
Preserving Access to Home Health Act of 2022
Client: AMEDISYS, INC. · Firm: BGR GOVERNMENT AFFAIRS
Strategic guidance and counsel on home health reimbursement and policy including The Preserving Access to Home Health Act of 2022 (S. 4605/ H.R. 8581)
Preserving Access to Home Health Act of 2022
Client: AMEDISYS, INC. · Firm: BGR GOVERNMENT AFFAIRS
Strategic guidance and counsel on home health reimbursement and policy including The Preserving Access to Home Health Act of 2022 (S. 4605/ H.R. 8581)
Restore Protections for Dialysis Patients Act
Client: KIDNEY CARE PARTNERS · Firm: BGR GOVERNMENT AFFAIRS
Provide guidance, and strategic counsel on federal regulatory policy and legislative issues affecting the quality of kidney care and treatment including the ESRD Prospective Payment System Regulation and the Chronic Kidney Disease Improvement in Research and Treatment Act, Restore Protections for Dialysis Patients Act (H.R. 8594/S. 4750) and other bills impacting kidney care.
Restore Protections for Dialysis Patients Act
Client: KIDNEY CARE PARTNERS · Firm: BGR GOVERNMENT AFFAIRS
Provide guidance, and strategic counsel on federal regulatory policy and legislative issues affecting the quality of kidney care and treatment including the ESRD Prospective Payment System Regulation and the Chronic Kidney Disease Improvement in Research and Treatment Act, Restore Protections for Dialysis Patients Act (H.R. 8594/S. 4750) and other bills impacting kidney care.
Restore Protections for Dialysis Patients Act
Client: KIDNEY CARE PARTNERS · Firm: BGR GOVERNMENT AFFAIRS
Provide guidance, and strategic counsel on federal regulatory policy and legislative issues affecting the quality of kidney care and treatment including the ESRD Prospective Payment System Regulation and the Chronic Kidney Disease Improvement in Research and Treatment Act, Restore Protections for Dialysis Patients Act (H.R. 8594/S. 4750) and other bills impacting kidney care.
Restore Protections for Dialysis Patients Act
Client: KIDNEY CARE PARTNERS · Firm: BGR GOVERNMENT AFFAIRS
Provide guidance, and strategic counsel on federal regulatory policy and legislative issues affecting the quality of kidney care and treatment including the ESRD Prospective Payment System Regulation and the Chronic Kidney Disease Improvement in Research and Treatment Act, Restore Protections for Dialysis Patients Act (H.R. 8594/S. 4750) and other bills impacting kidney care.
Preserving Access to Home Health Act of 2022
Client: AMEDISYS, INC. · Firm: BGR GOVERNMENT AFFAIRS
Strategic guidance and counsel on home health reimbursement and policy including The Preserving Access to Home Health Act of 2022 (S. 4605/ H.R. 8581)
Preserving Access to Home Health Act of 2022
Client: AMEDISYS, INC. · Firm: BGR GOVERNMENT AFFAIRS
Strategic guidance and counsel on home health reimbursement and policy including The Preserving Access to Home Health Act of 2022 (S. 4605/ H.R. 8581)
Preserving Access to Home Health Act of 2022
Client: AMEDISYS, INC. · Firm: BGR GOVERNMENT AFFAIRS
Strategic guidance and counsel on home health reimbursement and policy including The Preserving Access to Home Health Act of 2022 (S. 4605/ H.R. 8581)
Preserving Access to Home Health Act of 2022
Client: AMEDISYS, INC. · Firm: BGR GOVERNMENT AFFAIRS
Strategic guidance and counsel on home health reimbursement and policy including The Preserving Access to Home Health Act of 2022 (S. 4605/ H.R. 8581)
Restore Protections for Dialysis Patients Act
Client: KIDNEY CARE PARTNERS · Firm: BGR GOVERNMENT AFFAIRS
Provide guidance, and strategic counsel on federal regulatory policy and legislative issues affecting the quality of kidney care and treatment including the ESRD Prospective Payment System Regulation and the Chronic Kidney Disease Improvement in Research and Treatment Act, Restore Protections for Dialysis Patients Act (H.R. 8594/S. 4750) and other bills impacting kidney care.
Restore Protections for Dialysis Patients Act
Client: KIDNEY CARE PARTNERS · Firm: BGR GOVERNMENT AFFAIRS
Provide guidance, and strategic counsel on federal regulatory policy and legislative issues affecting the quality of kidney care and treatment including the ESRD Prospective Payment System Regulation and the Chronic Kidney Disease Improvement in Research and Treatment Act, Restore Protections for Dialysis Patients Act (H.R. 8594/S. 4750) and other bills impacting kidney care.
Restore Protections for Dialysis Patients Act
Client: KIDNEY CARE PARTNERS · Firm: BGR GOVERNMENT AFFAIRS
Provide guidance, and strategic counsel on federal regulatory policy and legislative issues affecting the quality of kidney care and treatment including the ESRD Prospective Payment System Regulation and the Chronic Kidney Disease Improvement in Research and Treatment Act, Restore Protections for Dialysis Patients Act (H.R. 8594/S. 4750) and other bills impacting kidney care.
Restore Protections for Dialysis Patients Act
Client: KIDNEY CARE PARTNERS · Firm: BGR GOVERNMENT AFFAIRS
Provide guidance, and strategic counsel on federal regulatory policy and legislative issues affecting the quality of kidney care and treatment including the ESRD Prospective Payment System Regulation and the Chronic Kidney Disease Improvement in Research and Treatment Act, Restore Protections for Dialysis Patients Act (H.R. 8594/S. 4750) and other bills impacting kidney care.
Long-Term Care Pharmacy Definition Act of 2021
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting the long-term care pharmacy industry; S.1574 / H.R.5632 - Long-Term Care Pharmacy Definition Act of 2021.
Long-Term Care Pharmacy Definition Act of 2021
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting the long-term care pharmacy industry; S.1574 / H.R.5632- Long-Term Care Pharmacy Definition Act of 2021.
Long-Term Care Pharmacy Definition Act of 2021
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting the long-term care pharmacy industry; S.1574 / H.R.5632 - Long-Term Care Pharmacy Definition Act of 2021.
Long-Term Care Pharmacy Definition Act of 2021
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting the long-term care pharmacy industry; S.1574 / H.R.5632- Long-Term Care Pharmacy Definition Act of 2021.
Preserving Access to Home Health Act of 2022
Client: AMEDISYS, INC. · Firm: BGR GOVERNMENT AFFAIRS
Strategic guidance and counsel on home health reimbursement and policy including The Preserving Access to Home Health Act of 2022 (S. 4605 / H.R. 8581)
Preserving Access to Home Health Act of 2022
Client: AMEDISYS, INC. · Firm: BGR GOVERNMENT AFFAIRS
Strategic guidance and counsel on home health reimbursement and policy including The Preserving Access to Home Health Act of 2022 (S. 4605 / H.R. 8581)
Restore Protections for Dialysis Patients Act
Client: KIDNEY CARE PARTNERS · Firm: BGR GOVERNMENT AFFAIRS
Provide guidance, and strategic counsel on federal regulatory policy and legislative issues affecting the quality of kidney care and treatment including the ESRD Prospective Payment System Regulation and the Chronic Kidney Disease Improvement in Research and Treatment Act, Restore Protections for Dialysis Patients Act (H.R. 8594/S. 4750) and other bills impacting kidney care.
Restore Protections for Dialysis Patients Act
Client: KIDNEY CARE PARTNERS · Firm: BGR GOVERNMENT AFFAIRS
Provide guidance, and strategic counsel on federal regulatory policy and legislative issues affecting the quality of kidney care and treatment including the ESRD Prospective Payment System Regulation and the Chronic Kidney Disease Improvement in Research and Treatment Act, Restore Protections for Dialysis Patients Act (H.R. 8594/S. 4750) and other bills impacting kidney care.
Long-Term Care Pharmacy Definition Act of 2021
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting the long-term care pharmacy industry; S.1574 / H.R.5632- Long-Term Care Pharmacy Definition Act of 2021.
Long-Term Care Pharmacy Definition Act of 2021
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting the long-term care pharmacy industry; S.1574 / H.R.5632 - Long-Term Care Pharmacy Definition Act of 2021.
Long-Term Care Pharmacy Definition Act of 2021
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting the long-term care pharmacy industry; S.1574 / H.R.5632 - Long-Term Care Pharmacy Definition Act of 2021.
Long-Term Care Pharmacy Definition Act of 2021
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting the long-term care pharmacy industry; S.1574 / H.R.5632- Long-Term Care Pharmacy Definition Act of 2021.
Preserving Access to Home Health Act of 2022
Client: AMEDISYS, INC. · Firm: BGR GOVERNMENT AFFAIRS
Strategic guidance and counsel on home health reimbursement and policy including The Preserving Access to Home Health Act of 2022 (S. 4605 / H.R. 8581)
Provide guidance and advocacy with regard to regulations and legislation that could impact the medical device industry generally, and Stryker Corporation specifically.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
MATRIX MEDICAL NETWORK via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and guidance on issues impacting the clinical services industry generally, and Matrix Medical Network specifically as well as issues relating to MA risk adjustment.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
BREAKTHROUGH T1D (F/K/A JDRF) via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocate on issues related to Type 1 Diabetes policy
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
GRADY HEALTH SYSTEM via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and policy advocacy related to federal payment and policy issues and government funding impacting hospitals generally and Grady Health System specifically
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, U.S. Postal Service (USPS)
NYU LANGONE HEALTH via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and policy analysis related to federal payment and policy issues and government funding impacting hospitals generally and NYU Langone Health specifically
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
ACADEMY OF NUTRITION AND DIETETICS via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocate on issues related to health care coverage for Medical Nutritional Therapy and Intensive behavior health and other priorities for the Academy of Nutrition and Dietetics
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PROLACTA BIOSCIENCE, INC. via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocate on issues related to regulation of, access to, and reimbursement for human-milk based exempt formulas
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
MASS GENERAL BRIGHAM (FORMERLY KNOWN AS PARTNERS HEALTHCARE) via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and policy analysis related to federal payment and policy issues and government funding impacting hospitals and health plans generally and Mass General Brigham specifically
Filing targets: Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), SENATE
PTC THERAPEUTICS via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide guidance and advocacy with regard to regulations and legislation that could impact the pharmaceutical industry generally, and PTC specifically.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SCP-HEALTH via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic guidance and counsel on policy issues impacting emergency medicine and issues related to acute unscheduled care including physician fee schedule
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
AKEBIA THERAPEUTICS, INC. via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic guidance and counsel on issues impacting the biopharmaceutical industry and legislation to provide greater access to kidney care.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
AMERICAN SOCIETY OF GENE AND CELL THERAPY via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Strategic advice and counsel on issues impacting gene and cell therapy development and access
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
WALGREEN CO. via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide policy analysis, strategic advice and direct advocacy support to Walgreens related to public policy priorities for the retail pharmacy industry
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE, White House Office
EDWARDS LIFESCIENCES LLC via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide analysis and strategic advocacy support services to Edwards Lifesciences public policy priorities, including FDA regulatory and CMS coverage and reimbursement issue
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BIOTECHNOLOGY INNOVATION ORGANIZATION via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Advise and advocate on client's behalf regarding ongoing public policy concerns impacting the innovative biotechnology industry in Congress and throughout the Administration
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
CARDINAL HEALTH via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocate on issues related to health, tax and trade policy
Provide strategic counsel and advocate on issues related to health, tax and trade policy
Provide strategic counsel and advocate on issues related to health, tax and trade policy
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
CENTENE CORPORATION via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Strategic guidance and counsel related to Medicare, Medicaid, and the insurance market.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ADVOCATE HEALTH via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocate on health care policy, including matters impacting the hospital industry and federal appropriations
Provide strategic counsel and advocate on health care policy, including matters impacting the hospital industry and federal appropriations
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
NEUROCRINE BIOSCIENCES, INC. via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide guidance and strategic counsel with regard to regulations and legislation that could impact the biopharmaceutical industry generally such as drug pricing and telehealth policy
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
LOCKTON MANAGEMENT, LLC via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Strategic guidance and counsel on maintaining and strengthening the employer-based health care system, and advise the client on legislative and regulatory issues.
Filing targets: Commodity Futures Trading Commission (CFTC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), Office of Science & Technology Policy (OSTP), SENATE, Securities & Exchange Commission (SEC), Transportation, Dept of (DOT), Treasury, Dept of
BIOMARIN PHARMACEUTICAL INC. via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocacy on issues relating to biopharmaceuticals for rare diseases driven by genetic causes generally, or BioMarin Pharmaceutical specifically.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
AMERICAN HEALTH CARE ASSOCIATION via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Long-term care reform; Medicare and Medicaid payment policy; Medicare Advantage policy; arbitration issues; implementation of health care reform; bad debt relief; SGR replacement; NOTICE Act; Nurse staffing mandate; appropriations
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
CHILDREN'S HOSPITAL AND HEALTH SYSTEM, INC. via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Health care reform and regulatory implementation and funding, Medicaid, Graduate Medical Education; CHIP Reauthorization; DSH Payments; FY'25 federal appropriations; mental health reform; H.R. 1 One Big Beautiful Bill Act
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
NOVARTIS via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies and EPIC Act
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies, EPIC Act; Most Favored Nation (MFN) policy, drug pricing policies
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FRESENIUS MEDICAL CARE NORTH AMERICA (FKA FRESENIUS MEDICAL CARE) via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Medicare reimbursement; End stage renal disease (ESRD) payment reforms; extension of Medicare sequester; telehealth policy and waivers; issues pertaining to Medicare Secondary Payer Act; oral-only ESRD drugs
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
REGENERON PHARMACEUTICALS, INC. via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocate on issues related to matters of importance to domestic pharmaceutical manufacturers
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
SELLERS DORSEY via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Strategic guidance and counsel on federal healthcare reform legislation activity and implementation; Medicaid
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
PFIZER, INC via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide guidance and strategic counsel with regard to regulations and legislation that could impact the pharmaceutical industry generally and/or Pfizer specifically.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
GLAXOSMITHKLINE, INC via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Strategic guidance and advocacy on health care related issues to include: healthcare reform, HIV/AIDS, bio-defense, Medicare/Medicaid and FDA
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocate on issues related to physician payment.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
PREMIA SPINE via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocate on issues related to the Company's reimbursement and coding priorities.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
PHI HEALTH, LLC, D/B/A PHI AIR MEDICAL via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocate on issues related to ambulance legislative and regulatory issues.
Provide strategic counsel and advocate on issues related to ambulance legislative and regulatory issues.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), SENATE
KING'S DAUGHTERS MEDICAL CENTER via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocate on issues related to health care funding, appropriations and federal lands.
Provide strategic counsel and advocate on issues related to health care funding, appropriations and federal lands
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
STAMFORD HEALTH via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and policy analysis related to federal payment and policy issues and government funding impacting hospitals generally and Stamford Health specifically
BECTON, DICKINSON AND COMPANY via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocate on issues related to medical device regulation, supply chains and trade
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
HELLO HEART, INC via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocate on issues related to healthcare policy
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
IOWA PRIMARY CARE ASSOCIATION (NATIONAL PRIMARY CARE ASSOCIATION HUB) via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocate on federal policy issues impacting community health centers
Filing targets: Centers For Medicare and Medicaid Services (CMS), Health & Human Services, Dept of (HHS)
NATIONAL ALLIANCE FOR CARE AT HOME via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocate on issues related to home health, home care and hospice policy
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
FEDERATION OF AMERICAN HOSPITALS via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocate on issues related to health policy and hospitals
Provide strategic counsel and advocate on issues related to health policy and hospitals
Filing targets: HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
ALLIANCE FOR REGENERATIVE MEDICINE via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic guidance and advocacy on issues related to regulation of, access to, and reimbursement for regenerative medicine products, and any other issues related to the Alliance for Regenerative Medicine specifically.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
TEXAS ESSENTIAL HEALTHCARE PARTNERSHIPS via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and policy advocacy related to to health care funding, access, and delivery, Medicaid financing and reimbursement
Filing targets: Centers For Medicare and Medicaid Services (CMS), Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
REAL TIME MEDICAL SYSTEMS via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel related to federal health care policy impacting nursing facilities and assisted living settings.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
FINDHELP via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocacy on federal health policy related to social care programs.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, Veterans Affairs, Dept of (VA), White House Office
LUMEXA IMAGING, INC. (FKA US RADIOLOGY SPECIALISTS) via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provided strategic counsel on matters before HHS and the Congress, including surprise medical billing and Medicare payment.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
RADIOLOGY PARTNERS via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provided strategic counsel on matters before HHS and the Congress, including surprise medical billing and Medicare payment.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
OAK STREET HEALTH D/B/A CVS HEALTH via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocacy on issues impacting value-based primary care centers for Medicare beneficiaries generally, and Oak Street Health specifically
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · RR
Provide strategic counsel and advocate on issues related to physician payment.
STAMFORD HEALTH via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and policy analysis related to federal payment and policy issues and government funding impacting hospitals generally and Stamford Health specifically
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALLIANCE FOR REGENERATIVE MEDICINE via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic guidance and advocacy on issues related to regulation of, access to, and reimbursement for regenerative medicine products, and any other issues related to the Alliance for Regenerative Medicine specifically.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
REAL TIME MEDICAL SYSTEMS via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel related to federal health care policy impacting nursing facilities and assisted living settings.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
FINDHELP via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocacy on federal health policy related to social care programs.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, Veterans Affairs, Dept of (VA), White House Office
BECTON, DICKINSON AND COMPANY via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocate on issues related to medical device regulation, supply chains and trade
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
LUMEXA IMAGING, INC. (FKA US RADIOLOGY SPECIALISTS) via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provided strategic counsel on matters before HHS and the Congress, including surprise medical billing and Medicare payment.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
RADIOLOGY PARTNERS via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provided strategic counsel on matters before HHS and the Congress, including surprise medical billing and Medicare payment.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
OAK STREET HEALTH D/B/A CVS HEALTH via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocacy on issues impacting value-based primary care centers for Medicare beneficiaries generally, and Oak Street Healthspecifically
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
MLK COMMUNITY HEALTHCARE via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide guidance and advocacy with regard to federal regulations and legislation that could impact non-profit health care providers generally, or MLK Community Healthcare specifically.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
IOWA PRIMARY CARE ASSOCIATION (NATIONAL PRIMARY CARE ASSOCIATION HUB) via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocate on federal policy issues impacting community health centers
Filing targets: Centers For Medicare and Medicaid Services (CMS), Health & Human Services, Dept of (HHS), White House Office
STRYKER CORPORATION via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide guidance and advocacy with regard to regulations and legislation that could impact the medical device industry generally, and Stryker Corporation specifically.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
MATRIX MEDICAL NETWORK via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and guidance on issues impacting the clinical services industry generally, and Matrix Medical Network specifically as well as issues relating to MA risk adjustment.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
PREMIA SPINE via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocate on issues related to the Company's reimbursement and coding priorities.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
MASS GENERAL BRIGHAM (FORMERLY KNOWN AS PARTNERS HEALTHCARE) via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and policy analysis related to federal payment and policy issues and government funding impacting hospitals and health plans generally and Mass General Brigham specifically
Filing targets: Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), SENATE
PTC THERAPEUTICS via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide guidance and advocacy with regard to regulations and legislation that could impact the pharmaceutical industry generally, and PTC specifically.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SCP-HEALTH via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic guidance and counsel on policy issues impacting emergency medicine and issues related to acute unscheduled care including physician fee schedule
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
AKEBIA THERAPEUTICS, INC. via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic guidance and counsel on issues impacting the biopharmaceutical industry and legislation to provide greater access to kidney care.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PHI HEALTH, LLC, D/B/A PHI AIR MEDICAL via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocate on issues related to ambulance legislative and regulatory issues.
Provide strategic counsel and advocate on issues related to ambulance legislative and regulatory issues.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), SENATE
KING'S DAUGHTERS MEDICAL CENTER via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocate on issues related to health care funding, appropriations and federal lands.
Provide strategic counsel and advocate on issues related to health care funding, appropriations and federal lands
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN SOCIETY OF GENE AND CELL THERAPY via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Strategic advice and counsel on issues impacting gene and cell therapy development and access
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
WALGREEN CO. via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide policy analysis, strategic advice and direct advocacy support to Walgreens related to public policy priorities for the retail pharmacy industry
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
EDWARDS LIFESCIENCES LLC via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide analysis and strategic advocacy support services to Edwards Lifesciences public policy priorities, including FDA regulatory and CMS coverage and reimbursement issue
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
NATIONAL ALLIANCE FOR CARE AT HOME via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocate on issues related to home health, home care and hospice policy
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
TEXAS ESSENTIAL HEALTHCARE PARTNERSHIPS via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and policy advocacy related to to health care funding, access, and delivery, Medicaid financing and reimbursement
Filing targets: Centers For Medicare and Medicaid Services (CMS), Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
BIOTECHNOLOGY INNOVATION ORGANIZATION via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Advise and advocate on client's behalf regarding ongoing public policy concerns impacting the innovative biotechnology industry in Congress and throughout the Administration
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
CARDINAL HEALTH via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocate on issues related to health, tax and trade policy
Provide strategic counsel and advocate on issues related to health, tax and trade policy
Provide strategic counsel and advocate on issues related to health, tax and trade policy
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
CENTENE CORPORATION via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Strategic guidance and counsel related to Medicare, Medicaid, and the insurance market.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
AMEDISYS, INC. via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Strategic guidance and counsel on home health reimbursement and policy including The Preserving Access to Home Health Act (S. 4605/ H.R. 8581)
GRADY HEALTH SYSTEM via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and policy advocacy related to federal payment and policy issues and government funding impacting hospitals generally and Grady Health System specifically
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
HELLO HEART, INC via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocate on issues related to healthcare policy
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
NEUROCRINE BIOSCIENCES, INC. via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide guidance and strategic counsel with regard to regulations and legislation that could impact the biopharmaceutical industry generally such as drug pricing and telehealth policy
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
FEDERATION OF AMERICAN HOSPITALS via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocate on issues related to health policy and hospitals
Provide strategic counsel and advocate on issues related to health policy and hospitals
Filing targets: HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
LOCKTON MANAGEMENT, LLC via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Strategic guidance and counsel on maintaining and strengthening the employer-based health care system, and advise the client on legislative and regulatory issues.
Filing targets: Commodity Futures Trading Commission (CFTC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Science & Technology Policy (OSTP), SENATE, Securities & Exchange Commission (SEC), Transportation, Dept of (DOT), Treasury, Dept of
NYU LANGONE HEALTH via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and policy analysis related to federal payment and policy issues and government funding impacting hospitals generally and NYU Langone Health specifically
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
ACADEMY OF NUTRITION AND DIETETICS via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocate on issues related to health care coverage for Medical Nutritional Therapy and Intensive behavior health and other priorities for the Academy of Nutrition and Dietetics
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PROLACTA BIOSCIENCE, INC. via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocate on issues related to regulation of, access to, and reimbursement for human-milk based exempt formulas
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
AMERICAN HEALTH CARE ASSOCIATION via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Long-term care reform; Medicare and Medicaid payment policy; Medicare Advantage policy; arbitration issues; implementation of health care reform; bad debt relief; SGR replacement; NOTICE Act; Nurse staffing mandate; appropriations
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
CHILDREN'S HOSPITAL AND HEALTH SYSTEM, INC. via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Health care reform and regulatory implementation and funding, Medicaid, Graduate Medical Education; CHIP Reauthorization; DSH Payments; FY'25 federal appropriations; mental health reform; H.R. 1 One Big Beautiful Bill Act
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
FRESENIUS MEDICAL CARE NORTH AMERICA (FKA FRESENIUS MEDICAL CARE) via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Medicare reimbursement; End stage renal disease (ESRD) payment reforms; extension of Medicare sequester; telehealth policy and waivers; issues pertaining to Medicare Secondary Payer Act; oral-only ESRD drugs
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BREAKTHROUGH T1D (F/K/A JDRF) via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocate on issues related to Type 1 Diabetes policy
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ADVOCATE HEALTH via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocate on health care policy, including matters impacting the hospital industry and federal appropriations
Provide strategic counsel and advocate on health care policy, including matters impacting the hospital industry and federal appropriations
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
REGENERON PHARMACEUTICALS, INC. via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocate on issues related to matters of importance to domestic pharmaceutical manufacturers
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BIOMARIN PHARMACEUTICAL INC. via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocacy on issues relating to biopharmaceuticals for rare diseases driven by genetic causes generally, or BioMarin Pharmaceutical specifically.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
SELLERS DORSEY via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Strategic guidance and counsel on federal healthcare reform legislation activity and implementation; Medicaid
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PFIZER, INC via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide guidance and strategic counsel with regard to regulations and legislation that could impact the pharmaceutical industry generally and/or Pfizer specifically.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
GLAXOSMITHKLINE, INC via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Strategic guidance and advocacy on health care related issues to include: healthcare reform, HIV/AIDS, bio-defense, Medicare/Medicaid and FDA
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NOVARTIS via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies and EPIC Act
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies, EPIC Act; Most Favored Nation (MFN) policy, drug pricing policies
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PREMIA SPINE via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · RR
Provide strategic counsel and advocate on issues related to the Company's reimbursement and coding priorities.
PHI HEALTH, LLC, D/B/A PHI AIR MEDICAL via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · RR
Provide strategic counsel and advocate on issues related to ambulance legislative and regulatory issues.
Provide strategic counsel and advocate on issues related to ambulance legislative and regulatory issues.
KING'S DAUGHTERS MEDICAL CENTER via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · RR
Provide strategic counsel and advocate on issues related to health care funding, appropriations and federal lands.
Provide strategic counsel and advocate on issues related to health care funding, appropriations and federal lands.
SCP-HEALTH via BGR GOVERNMENT AFFAIRS
2026 · first_quarter · 1A
Provide strategic guidance and counsel on policy issues impacting emergency medicine and issues related to acute unscheduled care including physician fee schedule
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
HELLO HEART, INC via BGR GOVERNMENT AFFAIRS
2026 · first_quarter · 1A
Provide strategic counsel and advocate on issues related to healthcare policy
Filing targets: Centers For Medicare and Medicaid Services (CMS), Health & Human Services, Dept of (HHS), White House Office